Literature DB >> 32536268

Impaired wound healing in a migraine patient as a possible side effect of calcitonin gene-related peptide receptor antibody treatment: A case report.

Sebastian Wurthmann1, Steffen Nägel1,2, Eva Hadaschik3, Swantje Schlott3, Armin Scheffler1, Christoph Kleinschnitz1, Dagny Holle1.   

Abstract

INTRODUCTION: Wound healing disturbances as possible side effects of calcitonin gene-related peptide (CGRP) antibody treatment have been discussed previously but not yet described in humans. Basic research suggests that calcitonin gene-related peptide plays an important role in keratinocyte migration, vascularization and immune response and lack of calcitonin gene-related peptide may lead to impaired wound healing. CASE: A 51-year-old female migraine patient was treated with the CGRP receptor antibody erenumab for 6 months, which led to a relevant reduction of migraine days. During the treatment, two periods of severely impaired wound healing occurred after a trivial skin injury without spatial relation to the injection site. Skin biopsy confirmed a deep perivascular and interstitial lymphohistiocytic infiltrate with admixed eosinophils, ulceration of the epithelium, a heavy edema of the papillary dermis and focally thrombosed vessels.
CONCLUSION: Impaired wound healing might be relevant side effects of CGRP antibody therapy and anamnesis within the course of treatment should also include possible observation of impaired wound healing or planned surgery.

Entities:  

Keywords:  CGRP; CGRP receptor antibody; Migraine; prophylactic treatment; wound healing disturbance

Year:  2020        PMID: 32536268     DOI: 10.1177/0333102420933571

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  5 in total

1.  First Report of Symmetrical Drug-related Intertriginous and Flexural Exanthema (SDRIFE or Baboon Syndrome) After Erenumab Application for Migraine Prevention.

Authors:  Carl H Göbel; Axel Heinze; Sarah Karstedt; Anna Cirkel; Thomas F Münte; Hartmut Göbel
Journal:  Pain Ther       Date:  2022-07-31

2.  Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study.

Authors:  Hannah Schenk; Dagny Holle; Michael Nsaka; Christoph Kleinschnitz; Martin Glas; Armin Scheffler
Journal:  J Headache Pain       Date:  2022-05-11       Impact factor: 7.277

Review 3.  The putative role of trigemino-vascular system in brain perfusion homeostasis and the significance of the migraine attack.

Authors:  Roberto De Simone; Mattia Sansone; Cinzia Russo; Angelo Miele; Antonio Stornaiuolo; Simone Braca
Journal:  Neurol Sci       Date:  2022-07-08       Impact factor: 3.830

4.  Extreme ecchymoses in a migraine patient using concomitant treatment with calcitonin gene-related peptide receptor antibodies and fish oil supplements: a case report.

Authors:  C K Cullum; M K Olsen; H B Kocadag; M Ashina; F M Amin
Journal:  BMC Neurol       Date:  2021-07-02       Impact factor: 2.474

Review 5.  The Local Neuropeptide System of Keratinocytes.

Authors:  Nicola Cirillo
Journal:  Biomedicines       Date:  2021-12-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.